Northern Trust
CTNM

Northern Trust’s Contineum Therapeutics CTNM Stock Holding History

Northern Trust’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55M Buy
277,804
+211,876
+321% +$2.78M ﹤0.01% 2670
2026
Q1 		$861K Buy
65,928
+12,052
+22% +$162K ﹤0.01% 3408
2025
Q4 		$616K Buy
53,876
+4,913
+10% +$56.1K ﹤0.01% 3585
2025
Q3 		$575K Buy
48,963
+23,794
+95% +$192K ﹤0.01% 3603
2025
Q2 		$99.9K Sell
25,169
-58,457
-70% -$254K ﹤0.01% 4111
2025
Q1 		$584K Sell
83,626
-5,636
-6% -$51.3K ﹤0.01% 3514
2024
Q4 		$1.31M Buy
89,262
+26,545
+42% +$420K ﹤0.01% 3258
2024
Q3 		$1.2M Buy
62,717
+43,340
+224% +$831K ﹤0.01% 3276
2024
Q2 		$341K Buy
+19,377
New +$312K ﹤0.01% 3645

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust's CTNM Position: Q2 2026 in Review

Northern Trust increased its Contineum Therapeutics (CTNM) stake by 321% in Q2 2026, buying an estimated $2.78M and bringing the position to 277,804 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2670.

Northern Trust first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Northern Trust held 277,804 shares of Contineum Therapeutics worth $4.55M as of Q2 2026.
  • Northern Trust bought 211,876 Contineum Therapeutics shares in Q2 2026, an estimated $2.78M.
  • Contineum Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2670 holding.
  • Northern Trust first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.